Title : A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Pub. Date : 2012 Oct 18

PMID : 22139083






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Perhaps explaining this finding, EOC patients with the KRAS variant were significantly more likely to be platinum resistant (odds ratio=3.18, confidence interval: 1.31-7.72, P=0.0106, n=291). Platinum KRAS proto-oncogene, GTPase Homo sapiens
2 These findings confirm the importance of the KRAS variant in EOC, and indicate that the KRAS variant is a biomarker of poor outcome in EOC likely due to platinum resistance. Platinum KRAS proto-oncogene, GTPase Homo sapiens